Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP-PEI-siRNA
- Development stage
- Preclinical
- Lead developer
- University of Washington
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intravenous, Intracerebroventricular, Inhalation, Intranasal, Intratracheal, Topical, Ophthalmic, Oral, Endoscopic Gastrointestinal
01
Overview
NP-PEI-siRNA is a nanovector formulation designed for siRNA delivery. It consists of polyethylene glycol (PEG) coated superparamagnetic iron oxide nanoparticles (NPs) with a 12 nm core diameter, further modified with a polycationic coating of polyethylenimine (PEI), and covalently functionalized with siRNA oligonucleotides. This nanovector aims to deliver siRNA to target cells for gene silencing. While it demonstrated efficacy in delivering siRNA and gene silencing in rat C6 glioblastoma cells, in vivo studies revealed severe hemoincompatibility and damage to the liver and spleen, indicating safety concerns compared to a poly-l-arginine (pArg) coated counterpart.
Beyond the preview
Go deeper on NP-PEI-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP-PEI-siRNA.